Quick Facts

• Therapeutic Focus: Addresses systemic and superficial fungal infections.
• Key Uses: Management of conditions such as blastomycosis, histoplasmosis, and aspergillosis.
• Other Applications: Used in the care of fungal infections of the nails (onychomycosis) and certain types of candidiasis.

---

What Itrakonazol PharmaS treats: Main Uses and Benefits

Itrakonazol PharmaS is a prescribed medication intended for the management of a range of fungal infections. It is generally administered to address systemic mycoses, which are infections that may involve internal organs or spread throughout the body.

Common Therapeutic Domains:

• Systemic Fungal Infections: The medication is indicated for use in the treatment of conditions like blastomycosis, histoplasmosis, and aspergillosis.
• Superficial Infections: It is also used to manage fungal infections that affect the skin, nails, and mucous membranes. This includes onychomycosis (fungal infection of the fingernails or toenails) and certain forms of candidiasis, such as those affecting the mouth or throat.

Official Eligibility and Non-Eligibility Rules

Itrakonazol PharmaS (Itraconazole) is approved for use in adult patients with systemic fungal infections. Eligibility is strictly defined by government regulatory agencies based on underlying conditions and age.

Populations for Whom Use is Contraindicated:

• Hypersensitivity: Patients with a known allergy to Itraconazole or any component of the formulation.
• Cardiovascular History: The medicine is contraindicated for the treatment of fungal nail infections (onychomycosis) in patients with Congestive Heart Failure (CHF) or a history of ventricular dysfunction.
• Pregnancy: Use is contraindicated for non-life-threatening indications. Women of childbearing potential must use highly effective contraception during therapy.
• Concomitant Drugs: Use is prohibited with several specific medications that are metabolized by CYP3A4 and carry a risk of serious cardiac events.

Populations Requiring Conditional Use:

• Age Groups: Use in the pediatric population (children) is not recommended as safety and efficacy have not been established. Use in elderly patients is advised only if the benefit outweighs the risks, considering potential decreases in organ function.
• Organ Function: Use requires caution and monitoring in patients with renal (kidney) or hepatic (liver) impairment due to limited clinical data. The drug is strongly discouraged in patients with active liver disease unless the infection is life-threatening.

Itraconazole is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, which is the primary mechanism for its extensive network of drug-drug interactions. Coadministration with other medicines metabolized by CYP3A4 can significantly increase their plasma concentrations, leading to a potentially higher risk of adverse effects.

Contraindicated Combinations: Due to the risk of life-threatening cardiac dysrhythmias or other serious events, coadministration is strictly contraindicated with specific medicines including, but not limited to, methadone, quinidine, dofetilide, dronedarone, disopyramide, ergot alkaloids (e.g., ergotamine, dihydroergotamine), irinotecan, and lurasidone.

Interactions Affecting Itraconazole Levels:

• CYP3A4 Inducers (e.g., rifampin, carbamazepine) can substantially decrease Itraconazole exposure, which may result in a loss of efficacy.
• Gastric Acid Reducers (e.g., proton pump inhibitors, H2-receptor antagonists) reduce gastric acidity, which is required for the adequate absorption of Itraconazole capsules. Reduced absorption can lead to lower, potentially sub-therapeutic drug levels.

Population-Specific Notes: Use requires caution and monitoring in patients with conditions such as Congestive Heart Failure or hepatic impairment.

Inhibiting Fungal Ergosterol Synthesis

Itraconazole acts as a non-competitive inhibitor of the fungal enzyme, lanosterol 14-alpha-demethylase (CYP51). The drug's molecule binds to the heme iron of this enzyme, effectively inactivating it. This targeted molecular action blocks a critical step in the ergosterol biosynthesis pathway, which is necessary for creating the fungal cell membrane.

---

Destabilizing the Fungal Cell Structure

Blocking the synthesis of ergosterol causes structurally compromised sterol precursors to accumulate inside the fungus. This mechanistic cascade leads to profound destabilization and increased permeability of the fungal cell membrane, which is the key physiological change that causes fungal cell damage and cell death.

---

Sustained Action via Active Metabolite

The drug is metabolized into an active compound, hydroxy-itraconazole, which shares the identical mechanism of action. This sustained mechanistic engagement results in continuous inhibition of the fungal enzyme, contributing to the prolonged disruption of the fungal integrity.

How to Use Itrakonazol PharmaS

Itraconazol PharmaS, which contains the active substance itraconazole, is administered either orally (as a capsule or solution) or via intravenous (IV) infusion. The administration route and specific dose regimen are designed to ensure proper drug delivery and absorption.

A critical principle of its use involves formulation-dependent timing relative to food. The capsule formulation is taken immediately following a full meal to maximize absorption, whereas the oral solution is administered on an empty stomach. Furthermore, to maintain optimal absorption, agents that reduce stomach acidity, such as antacids, are typically taken at least two hours before or two hours after the capsule dose. The capsules are swallowed whole and are not to be crushed, chewed, or opened.

Dosing frequency is determined by the total daily amount required. Doses exceeding 200 mg per day are typically divided and administered twice daily. For severe, life-threatening infections, an initial loading regimen of 200 mg two to three times daily may be utilized for three days. Treatment duration is variable; for example, certain fungal nail infections utilize a cyclic (pulse) schedule of seven days of dosing followed by a drug-free interval, while other systemic infections require continuous daily administration for several months. The IV formulation is generally reserved for patients who cannot tolerate oral administration.

Research evidence / Overview of studies for Itrakonazol PharmaS

Evidence for the Treatment of Endemic Systemic Fungal Infections

Research was studied for use in fungal infections that affect internal organs, such as blastomycosis and histoplasmosis. This evidence base includes both prospective clinical trials and observational settings, where research examined how individuals with mild-to-moderate forms of these conditions were observed over time. The studies primarily monitored outcomes related to systemic or functional imbalance, including laboratory mycological outcomes, outcomes related to physical discomfort, and radiographic monitoring.

Studies report how symptoms evolved in the observed populations over the course of treatment. The evidence contributes to understanding symptom patterns and outcomes in the observed patient populations.

However, the certainty remains low in some areas because the primary evidence for this use relies more heavily on non-randomized data and older prospective studies, compared to newer, large-scale RCTs. The results apply only to the populations studied, which often excludes patients who have the most severe forms of the condition. Also, limited information for long-term outcomes exists for some subsets, and follow-up durations were limited in some reports for certain conditions.

---

Evidence for Prophylaxis (Prevention) in Immunocompromised Patients

The evidence for using Itraconazole for prevention comes from Randomized Controlled Trials (RCTs). These trials research examined whether the rate of developing a systemic fungal infection differed in two groups of patients: those receiving Itraconazole and those receiving a control agent. The studies was evaluated in patients with advanced immune system issues, such as individuals with very low white blood cell counts (neutropenia) and patients with advanced HIV infection.

Research examined patient-reported outcomes describing perceived discomfort and outcomes describing episodic or acute changes related to infection. The RCTs reported patterns indicating fewer instances of infection in the group receiving the medicine than in the control group during the observation period. While trials was studied for infection rates, the findings were mixed when researchers examined outcomes like overall survival across all populations.

Data are still emerging regarding the optimal use of different formulations in prophylaxis. Studies monitored drug exposure in patients using the capsule versus the oral solution. Subgroup findings are uncertain concerning which patients benefit most from prophylaxis, and long-term effects are not fully established once the high-risk period has ended.

Key Studies & References

1. Clinical Practice Guidelines for the Management of Blastomycosis

Common questions about Itrakonazol PharmaS (FAQ)

Q: What is Itrakonazol PharmaS used for besides nail fungus?

Official regulatory documents indicate that Itrakonazol PharmaS is approved for treating specific serious internal fungal infections. These include conditions such as blastomycosis, histoplasmosis, and aspergillosis. It is utilized in situations where a systemic (body-wide) treatment is deemed appropriate to address the infection.

---

Q: Is Itrakonazol PharmaS the same as itraconazole from other companies?

Itrakonazol PharmaS is the brand name used by a specific company for its medicine. The active ingredient in this medicine is itraconazole. This indicates that the core therapeutic substance is identical, though product formulations and non-active components can vary across brands.

---

Q: What are the signs of a serious reaction to Itrakonazol PharmaS?

Official warnings highlight several serious risks. These can be indicated by signs related to liver problems, such as unusual fatigue, yellowing of the skin or eyes, and dark urine. Additionally, symptoms of heart failure, like sudden shortness of breath or notable swelling in the legs and feet, are key safety signals described in the product labeling. Severe skin reactions, such as blistering or extensive rash, are also documented as potential adverse reactions.

---

Q: Can people who are pregnant or breastfeeding use Itrakonazol PharmaS?

Regulatory information indicates that itraconazole is generally not recommended for use during pregnancy, especially for non-life-threatening conditions. Official rules indicate that women of childbearing potential must use highly effective contraception during treatment. Information regarding its use while breastfeeding is available for review by a healthcare provider.

---

Q: Can I take vitamins or supplements with Itrakonazol PharmaS?

Official documents state that Itrakonazol PharmaS interacts with many other medicines. This includes certain over-the-counter supplements and herbal products that affect an enzyme in the body called CYP3A4. Regulatory documents describe the importance of notifying a prescriber about all concurrent vitamins, supplements, and herbal remedies, as these substances can affect drug interaction risk.

---

Q: How do doctors monitor the effectiveness of Itrakonazol PharmaS treatment?

Effectiveness is typically monitored through clinical assessment, where doctors evaluate how the patient’s symptoms are evolving. For certain severe infections, therapeutic drug monitoring (TDM) may be performed. TDM involves measuring the concentration of itraconazole in the blood as a guide to assess drug exposure.

---

Q: Is Itrakonazol PharmaS used for skin infections, or only internal ones?

While the medicine is primarily categorized as a systemic antifungal used for serious internal infections, it is also approved for treating certain superficial infections that require treatment throughout the body. An example of this is fungal infections of the nails (onychomycosis).

---

Q: What is the maximum duration of treatment with Itrakonazol PharmaS?

The required duration of treatment is highly variable and depends entirely on the type and severity of the infection being addressed. Treatment can range from a few weeks using a pulse regimen to continuous administration for many months for deep-seated systemic infections. The total treatment length is outlined in the regulatory documentation and depends on the specific fungal infection being treated.

---

Q: How long does it usually take for Itrakonazol PharmaS to start working for fungal infections?

While the active substance reaches its peak level in the blood relatively quickly, it must build up and reach stable concentrations in the affected tissues, which can take about 15 days. For infections in slow-growing tissues like the skin or nails, it may take several weeks or months to observe the full therapeutic outcome.

---

Q: Is Itrakonazol PharmaS considered a strong antifungal medicine?

Itraconazole belongs to a class of medicines known as triazole antifungals. It is described as a broad-spectrum agent because it is effective against a wide range of fungi and is described as a key tool in the treatment of serious systemic infections.

---

Q: Do I need to change my diet while taking Itrakonazol PharmaS?

The capsule formulation requires specific conditions for proper absorption: it must be taken immediately after a full meal. Beyond this critical timing, official information indicates no mandatory general dietary changes. High-fat meals have been noted in studies to potentially increase absorption.

---

Q: What happens if I miss a dose of Itrakonazol PharmaS?

Regulatory patient information describes how to proceed if a dose is missed, stating that specific instructions are provided by the healthcare professional. This information clarifies that a double dose should not be taken to compensate for the one that was missed.

---

Q: Can I drink alcohol in moderation while using Itrakonazol PharmaS?

Official information describes that consumption of alcohol is generally not recommended during itraconazole treatment. This caution is related to the possibility of increasing the risk of side effects, including those affecting the liver and instances of dizziness.

---

Q: Does Itrakonazol PharmaS interact with birth control pills?

Official information indicates that itraconazole may have the potential to interact with hormonal contraceptive medicines. For non-life-threatening conditions, official rules indicate that women of childbearing potential must use a reliable, highly effective method of contraception during the course of therapy.

---

Q: How long does Itrakonazol PharmaS stay in your system after stopping?

Itraconazole's half-life in the blood is approximately 34 to 42 hours with repeated use. However, the active substance continues to persist in tissues like the nails and skin for a much longer period, often remaining detectable for weeks or even months after the last dose.

---

Q: Can Itrakonazol PharmaS be used to treat yeast infections?

Itraconazole is recognized in official sources for its broad spectrum of activity against many fungi and yeasts. This includes effectiveness against Candida species, indicating its utility in managing certain systemic yeast or fungal infections.

---

Q: Does Itrakonazol PharmaS affect driving ability?

Regulatory documents list side effects such as dizziness, somnolence (drowsiness), and temporary hearing loss. If any of these documented effects are experienced, the ability to safely drive or operate heavy machinery may be described as being potentially impaired.

---

Q: Is it safe to stop taking Itrakonazol PharmaS as soon as symptoms disappear?

The full course of medication is described in patient instructions as necessary to fully eradicate the fungal infection. Stopping treatment too early may result in the infection returning and may contribute to the development of resistance.

---

Q: Does Itrakonazol PharmaS cause temporary changes to taste or smell?

Alterations in the sense of taste, medically known as dysgeusia, have been reported as a possible side effect of itraconazole according to official product information.

---

Q: Is a metallic taste in the mouth a common side effect of Itrakonazol PharmaS?

Regulatory adverse reaction lists mention 'altered taste' as a reported side effect. For some patients, this taste alteration may be experienced as a metallic taste, though specific product information does not universally label it as a common symptom.

---

Q: Is Itrakonazol PharmaS effective for ringworm?

Itraconazole is effective against dermatophytes, which are the group of fungi that are responsible for causing ringworm (tinea) infections. The drug's activity against dermatophytes is described in official sources, which is the basis for its use in treating ringworm and related conditions.

---

Q: Why is it important to complete the full course of Itrakonazol PharmaS?

Completing the entire course is described in patient information as necessary for the successful management of the fungal infection. Patient instructions note that prematurely stopping the treatment can lead to the infection returning or not being fully eradicated, and may also contribute to the risk of drug resistance.

Storage & Disposal Scope

Item	Requirement (Official Regulatory Statement)
Labeled storage temperature	Store at a controlled room temperature, typically between 15 C to 25 C (59 F to 77 F), or below 25 C [NIH Source, EMA SmPC].
Light/moisture protection	Must be protected from light and protected from moisture [NIH Source, EMA SmPC].
Handling requirements	Keep from freezing [NIH Source]. Keep the container tightly closed and in the original package [NIH Source, EMA SmPC].
Disposal instructions	Dispose of any medicine you do not use according to local regulations or by following FDA guidelines [EMA SmPC, NIH Source]. Do not flush most unused medicines unless specifically instructed.
Child-protection storage	Keep out of the reach and sight of children [NIH Source, FDA Label].

Resulting Storage & Disposal Structure

Official storage and disposal statements require that the capsules be maintained at a controlled room temperature to ensure product stability. The medicine must remain sealed in its original packaging to protect it from light and moisture, and it must be kept from freezing. All unused or expired product must be disposed of following official national or local guidelines, which often recommend drug take-back programs or specific methods for household trash disposal.